Combining EZH2 and HDAC inhibitors to target castration-resistant prostate cancers.

Published in: PLoS biology (2023)

Development of resistance in castration-resistant prostate cancer (CRPC) involves epigenetic pathways. A new study in PLOS Biology demonstrates that combined therapy targeting enhancer of zeste homolog 2 (EZH2) and histone deacetylases (HDACs) may sensitize CRPC to both epigenetic and standard therapies.

Keyphrases

dna methylation
gene expression
prostate cancer
long noncoding rna
long non coding rna
transcription factor
stem cells
benign prostatic hyperplasia
mesenchymal stem cells
histone deacetylase
young adults
drug delivery
cell therapy